Phase 3 Clinical Study of Favipiravir in Patients with COVID-19 Non-Severe Pneumonia
Phase 3
Completed
- Conditions
- Patients with COVID-19 non-severe pneumonia
- Registration Number
- JPRN-jRCT2080225142
- Lead Sponsor
- FUJIFILM Toyama Chemical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 96
Inclusion Criteria
1 Age: 20 to 74 years inclusive
2.Sex: No restriction
3 Out patient/hospitalization: Hospitalization
4 Laboratory (RT-PCR) confirmed infection with SARS-CoV-2.
5 Lung involvement confirmed with chest imaging
6 Patients with fever of 37.5 degrees Celsius or more
7 Have a negative pregnancy test before study treatment
8 Others
Exclusion Criteria
1 Ten days or more have passed since the fever (37.5 degrees Celsius or more) started.
2 Patients who are pregnant or may be pregnant
3 Patients with severe hepatic or renal impairment
4 Others
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method